Global psychedelic drugs market is projected to register a substantial CAGR of 13.3% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.
Market Segmentation:
Global Psychedelic Drugs Market, By Source (Synthetic & Natural), Type (Empathogens, Dissociatives & Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy), Country (North America, Europe, Asia-Pacific, Middle East and Africa and South America) Industry Trends and Forecast to 2029.
Some of the major factors contributing to the growth of the global psychedylic drugs market are:
Growing acceptance of psychedelic drugs for treating depression
Increasing Prevalence Of Depression And Mental Disorders
Market Players:
The key market players for global psychedelic drugs market are listed below:
Jazz Pharmaceuticals, Inc.
Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.)
Hikma Pharmaceuticals PLC
COMPASS
Verrian
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Avadel
Celon Pharma SA.
Cybin Corp.
GH Research
Entheon Biomedical Corp
PharmaTher Holdings Ltd.
NRx Pharmaceuticals, Inc.
usonainstitute.org
TABLE OF CONTENTS
1 INTRODUCTION 25
- 1.1 OBJECTIVES OF THE STUDY 25
- 1.2 MARKET DEFINITION 25
- 1.3 OVERVIEW OF GLOBAL PSYCHEDELIC DRUGS MARKET 25
- 1.4 LIMITATIONS 27
- 1.5 MARKETS COVERED 27
2 MARKET SEGMENTATION 30
- 2.1 MARKETS COVERED 30
- 2.2 GEOGRAPHICAL SCOPE 31
- 2.3 YEARS CONSIDERED FOR THE STUDY 32
- 2.4 CURRENCY AND PRICING 32
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
- 2.6 MULTIVARIATE MODELLING 36
- 2.7 TYPE LIFELINE CURVE 36
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
- 2.9 DBMR MARKET POSITION GRID 38
- 2.10 MARKET END USER COVERAGE GRID 39
- 2.11 VENDOR SHARE ANALYSIS 40
- 2.12 SECONDARY SOURCES 41
- 2.13 ASSUMPTIONS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHT 46
- 4.1 PIPELINE ANALYSIS 48
- 4.2 PESTEL ANALYSIS 50
- 4.3 PORTER'S FIVE FORCES MODEL 51
5 REGULATORY FRAMEWORK: GLOBAL PSYCHEDELIC DRUGS MARKET 52
- 5.1 REGULATORY SCENARIO IN THE U.S. 52
- 5.2 REGULATORY SCENARIO IN THE U.K. 53
- 5.3 REGULATORY SCENARIO IN INDIA 54
- 5.4 REGULATORY SCENARIO IN UAE 54
- 5.5 REGULATORY SCENARIO IN AFRICA 55
- 5.6 REGULATORY SCENARIO IN BRAZIL 55
6 MARKET OVERVIEW 57
- 6.1 DRIVERS 59
- 6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS TO TREAT DEPRESSION 59
- 6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS 61
- 6.1.3 RISING AWARENESS TOWARD MENTAL HEALTH 64
- 6.1.4 ONGOING CLINICAL TRIALS 65
- 6.1.5 RISE IN PRODUCT APPROVALS 66
- 6.2 RESTRAINTS 66
- 6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS 66
- 6.2.2 HIGH COST OF PSYCHEDELIC DRUGS 69
- 6.2.3 PATENT EXPIRY OF PSYCHEDELIC DRUGS 70
- 6.3 OPPORTUNITIES 71
- 6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS 71
- 6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY 73
- 6.3.3 UPCOMING REHABILITATION CENTERS 74
- 6.3.4 AVAILABILITY OF CERTIFIED HEALTHCARE PROFESSIONALS 75
- 6.4 CHALLENGES 75
- 6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS 75
- 6.4.2 RISE IN ILLEGAL ALTERNATIVES 77
- 6.4.3 AVAILABILITY OF OTHER TREATMENT OPTIONS 77
7 COVID-19 IMPACT ON THE GLOBAL PSYCHEDELIC DRUGS MARKET 78
- 7.1 IMPACT ON PRICE 78
- 7.2 IMPACT ON DEMAND 78
- 7.3 IMPACT ON SUPPLY CHAIN 79
- 7.4 STRATEGIC DECISIONS FOR MANUFACTURERS 79
- 7.5 CONCLUSION 80
8 GLOBAL PSYCHEDELIC DRUGS MARKET, BY TYPE 81
- 8.1 OVERVIEW 82
- 8.2 EMPATHOGENS 85
- 8.3 DISSOCIATIVES 86
- 8.4 OTHERS 87
9 GLOBAL PSYCHEDELIC DRUGS MARKET, BY SOURCE 88
- 9.1 OVERVIEW 89
- 9.2 SYNTHETIC 92
- 9.3 NATURAL 93
10 GLOBAL PSYCHEDELIC DRUGS MARKET, BY DRUGS 94
- 10.1 OVERVIEW 95
- 10.2 GAMMA-HYDROXYBUTYRIC ACID 98
- 10.3 KETAMINE 99
- 10.4 PSILOCYBIN 100
- 10.5 OTHERS 101
11 GLOBAL PSYCHEDELIC DRUGS MARKET, BY APPLICATION 102
- 11.1 OVERVIEW 103
- 11.2 NARCOLEPSY 106
- 11.3 TREATMENT RESISTANT DEPRESSION 107
- 11.4 MAJOR DEPRESSIVE DISORDER 108
- 11.5 OPIATE ADDICTION 109
- 11.6 POST-TRAUMATIC STRESS DISORDER 110
- 11.7 OTHERS 111
12 GLOBAL PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION 112
- 12.1 OVERVIEW 113
- 12.2 ORAL 116
- 12.3 INHALATION 117
- 12.4 INJECTABLE 118
13 GLOBAL PSYCHEDELIC DRUGS MARKET, BY END USER 119
- 13.1 OVERVIEW 120
- 13.2 HOSPITALS 123
- 13.3 SPECIALTY CLINICS 124
- 13.4 HOMECARE 125
- 13.5 OTHERS 126
14 GLOBAL PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL 127
- 14.1 OVERVIEW 128
- 14.2 HOSPITALS PHARMACY 131
- 14.3 RETAIL PHARMACY 132
- 14.4 ONLINE PHARMACY 133
15 GLOBAL PSYCHEDELIC DRUGS MARKET, BY REGION 134
- 15.1 OVERVIEW 135
- 15.2 NORTH AMERICA 141
- 15.2.1 U.S. 148
- 15.2.2 CANADA 150
- 15.2.3 MEXICO 152
- 15.3 EUROPE 154
- 15.3.1 GERMANY 163
- 15.3.2 U.K. 165
- 15.3.3 FRANCE 168
- 15.3.4 ITALY 170
- 15.3.5 SPAIN 173
- 15.3.6 RUSSIA 175
- 15.3.7 POLAND 178
- 15.3.8 SWITZERLAND 181
- 15.3.9 NETHERLANDS 184
- 15.3.10 HUNGARY 187
- 15.3.11 AUSTRIA 190
- 15.3.12 NORWAY 193
- 15.3.13 IRELAND 196
- 15.3.14 BELGIUM 199
- 15.3.15 LITHUANIA 202
- 15.3.16 REST OF EUROPE 205
- 15.4 ASIA-PACIFIC 206
- 15.4.1 INDIA 214
- 15.4.2 AUSTRALIA 217
- 15.4.3 SOUTH KOREA 220
- 15.4.4 SINGAPORE 223
- 15.4.5 MALAYSIA 226
- 15.5 MIDDLE EAST & AFRICA 229
- 15.5.1 SAUDI ARABIA 237
- 15.5.2 ISRAEL 240
- 15.5.3 EGYPT 243
- 15.5.4 UAE 246
- 15.5.5 SOUTH AFRICA 248
- 15.6 SOUTH AMERICA 251
- 15.6.1 BRAZIL 259
- 15.6.2 ARGENTINA 262
- 15.6.3 REST OF SOUTH AMERICA 265
16 GLOBAL PSYCHEDELIC DRUGS MARKET: COMPANY LANDSCAPE 266
- 16.1 COMPANY SHARE ANALYSIS: GLOBAL 266
- 16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 267
- 16.3 COMPANY SHARE ANALYSIS: EUROPE 268
- 16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 269
17 SWOT ANALYSIS 270
18 COMPANY PROFILE 271
- 18.1 JAZZ PHARMACEUTICALS, INC. 271
- 18.1.1 COMPANY SNAPSHOT 271
- 18.1.2 REVENUE ANALYSIS 272
- 18.1.3 COMPANY SHARE ANALYSIS 272
- 18.1.4 PRODUCT PORTFOLIO 272
- 18.1.5 RECENT DEVELOPMENTS 273
- 18.2 PFIZER INC. 274
- 18.2.1 COMPANY SNAPSHOT 274
- 18.2.2 REVENUE ANALYSIS 274
- 18.2.3 COMPANY SHARE ANALYSIS 275
- 18.2.4 PRODUCT PORTFOLIO 275
- 18.2.5 RECENT DEVELOPMENTS 275
- 18.3 F. HOFFMANN- LA ROCHE LTD 276
- 18.3.1 COMPANY SNAPSHOT 276
- 18.3.2 REVENUE ANALYSIS 276
- 18.3.3 COMPANY SHARE ANALYSIS 277
- 18.3.4 PRODUCT PORTFOLIO 277
- 18.3.5 RECENT DEVELOPMENT 277
- 18.4 JANSSEN GLOBAL SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 278
- 18.4.1 COMPANY SNAPSHOT 278
- 18.4.2 COMPANY SHARE ANALYSIS 278
- 18.4.3 PRODUCT PORTFOLIO 279
- 18.4.4 RECENT DEVELOPMENT 279
- 18.5 AVADEL 280
- 18.5.1 COMPANY SNAPSHOT 280
- 18.5.2 PRODUCT PORTFOLIO 280
- 18.5.3 RECENT DEVELOPMENT 280
- 18.6 CELON PHARMA SA 281
- 18.6.1 COMPANY SNAPSHOT 281
- 18.6.2 PRODUCT PORTFOLIO 281
- 18.6.3 RECENT DEVELOPMENT 281
- 18.7 COMPASS 282
- 18.7.1 COMPANY SNAPSHOT 282
- 18.7.2 PRODUCT PORTFOLIO 282
- 18.7.3 RECENT DEVELOPMENTS 282
- 18.8 CYBIN CORP. 283
- 18.8.1 COMPANY SNAPSHOT 283
- 18.8.2 PRODUCT PORTFOLIO 283
- 18.8.3 RECENT DEVELOPMENTS 283
- 18.9 ENTHEON BIOMEDICAL CORP 284
- 18.9.1 COMPANY SNAPSHOT 284
- 18.9.2 PRODUCT PORTFOLIO 284
- 18.9.3 RECENT DEVELOPMENT 284
- 18.10 GH RESEARCH 285
- 18.10.1 COMPANY SNAPSHOT 285
- 18.10.2 PRODUCT PORTFOLIO 285
- 18.10.3 RECENT DEVELOPMENT 285
- 18.11 HIKMA PHARMACEUTICALS PLC 286
- 18.11.1 COMPANY SNAPSHOT 286
- 18.11.2 REVENUE ANALYSIS 286
- 18.11.3 PRODUCT PORTFOLIO 287
- 18.11.4 RECENT DEVELOPMENTS 287
- 18.12 NRX PHARMACEUTICALS, INC. 288
- 18.12.1 COMPANY SNAPSHOT 288
- 18.12.2 PRODUCT PORTFOLIO 288
- 18.12.3 RECENT DEVELOPMENT 288
- 18.13 PHARMATHER HOLDINGS LTD. 289
- 18.13.1 COMPANY SNAPSHOT 289
- 18.13.2 PRODUCT PORTFOLIO 289
- 18.13.3 RECENT DEVELOPMENT 289
- 18.14 VERRIAN 290
- 18.14.1 COMPANY SNAPSHOT 290
- 18.14.2 PRODUCT PORTFOLIO 290
- 18.14.3 RECENT DEVELOPMENT 290
- 18.15 USONAINSTITUTE.ORG 291
- 18.15.1 COMPANY SNAPSHOT 291
- 18.15.2 PRODUCT PORTFOLIO 291
- 18.15.3 RECENT DEVELOPMENT 291
19 QUESTIONNAIRE 292
20 RELATED REPORTS 296